HOME >> BIOLOGY >> NEWS
High BMI doesn't always spell obesity, Jackson Laboratory researchers show

For years doctors have used the body mass index (BMI), a ratio of height and weight, to characterize the clinical weight status of their patients. The lower the number, the presumption goes, the leaner the person, and anyone with a BMI above 30 is characterized as obese and at high risk for the associated complications.

But the BMI has come under scrutiny lately, and other techniques that measure how the weight is distributed on the body are thought to provide a better way to assess risk. Now a study in mice by scientists at The Jackson Laboratory indicates that the usefulness of the BMI is suspect even at the genetic level.

In research published in PLoS Genetics, the investigators from Jackson and the J.L. Pettis VA Medical Center and led by Dr. Gary Churchill of Jackson used a combination of computational, molecular and genetic tools to identify locations on the mouse genome that influence adiposity (amount of body fat), overall body size and bone structure. Applying an analytical technique called "structural equation modeling" to the genetic and physical characteristics of mouse inbred crosses, the scientists went beyond the one-gene, one-trait approach to reveal the networks of effects created by the influence of multiple genes.

"We found that the genetic network affecting adiposity is separate from that affecting overall body size," Churchill says, "providing strong evidence that a high weight is not necessarily directly associated with a high percentage of fat."

At the clinical level, the research suggests that more refined measurements are needed to distinguish individuals with a large body mass from those who are truly obese and consequently at high risk for diabetes, heart disease and other disorders.

Churchill and colleagues at Jackson recently received a 5-year, $15.1 million National Institute of General Medical Sciences grant to form an interdisciplinary Center for Genome Dynamics to study compl
'"/>

Contact: Joyce Peterson
joyce.peterson@jax.org
207-288-6058
Jackson Laboratory
20-Jul-2006


Page: 1 2

Related biology news :

1. Heart intervention doesnt outweigh medicine in study
2. This party doesnt start until the hosts arrive
3. Failed experiment yields a biocontrol agent that doesnt trigger antibiotic resistance
4. Acetaminophen safe to use after heart attack but doesnt protect the heart
5. In stretching, pain doesnt equal gain; but if NO isnt producing, stretching wont help
6. Study finds evolution doesnt always favor bigger animals
7. If oxytocin eating role doesnt mature at birth, what other situations affect its impact?
8. Size doesnt matter
9. To sea or not to sea: When it comes to salmon sex, size sometimes doesnt matter
10. What the eye doesnt see
11. Exercise doesnt work for us all

Post Your Comments:
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4stcg3/india_sensors ... "India Sensors Market Forecast and Opportunities 2020" ... market is projected to grow at a CAGR ... automotive, industrial and healthcare sectors are the key ... addition, adoption of MEMS technology in sensors is ...
(Date:3/19/2015)... 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host Laura ... to pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/17/2015)... 2015  MecklerMedia Corporation (OTCQX: MECK) announced its ... robots ever held in New York ... 11-13, 2015 at the Javits Convention Center. ... include: Acorn Product Development; Axis NJ; c-Link Systems; ... Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; RoboKind; ...
Breaking Biology News(10 mins):India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
(Date:3/30/2015)... PMG Research, Benchmark Research, and ... formation of VaxCorps, a network of highly experienced, ... conduct of vaccine trials in healthy adult, elderly, ... successfully conducted over 500 phase I-III vaccine clinical ... influenza as well as a vast array of ...
(Date:3/30/2015)... IRVINE, Calif. , March 30, 2015 /PRNewswire/ ... that its subsidiary corporation, NuGene BioPharma, Inc. has ... board. Dr. Guan is an internationally ... After finishing his college education at Peking University, ... his Ph.D. degree from the University of North ...
(Date:3/30/2015)... ROCKVILLE, Md. , March 30, 2015 ... company dedicated to the acquisition, development and commercialization of ... for the global market with a commercial focus on ... China Food and Drug Administration (CFDA) has approved the ... trial in ovarian clear cell carcinoma (OCCC) patients for ...
(Date:3/30/2015)... 30, 2015  Spherix Incorporated (Nasdaq: SPEX ... fostering and monetization of intellectual property, today provided ... 3:13-cv-03494-M and  Spherix v. Uniden , Case No. ... for the Northern District of Texas ... v. Verizon, Case No. 1:14-cv-00721-GBL-TCB, in the ...
Breaking Biology Technology:PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 2Spherix Provides Update on Litigation vs. VTech, Uniden and Verizon 3
Cached News: